Introduction {#s1}
============

Noninvasive mechanical ventilation (NIV) is a rapidly emerging and increasingly cost-effective method used in the treatment of respiratory failure \[[@C1]\]. Unequal awareness, new treatment indications and rapid technical development may cause inequalities in NIV accessibility worldwide. Unfortunately, it has not yet been determined whether the reasons for these inequalities are country specific \[[@C2]\]. Surprisingly, in spite of "GOLD standard" NIV indications given in international guidelines, such as for acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) \[[@C3]\], there is evidence that NIV is underused, even in well-developed Western countries \[[@C4]\]. This implies the need to identify reasons explaining the observed region- and/or income-related barriers impairing appropriate NIV application. We therefore designed a survey to assess the global accessibility of NIV, as well as to address the income- and/or region-specific conditions (*i.e.* financial and educational) that could correlate with inappropriate use of NIV in both acute and chronic respiratory failure.

Material and methods {#s2}
====================

Survey {#s2a}
------

The general aims of our survey were to: 1) assess discrepancies in NIV application among different geographical regions and countries grouped according to their income level in terms of NIV (*i.e.* supply, delivery, location of use, training and reimbursement), and 2) assess reasons for NIV underuse according to evidence level in acute and chronic respiratory failure.

To address the key questions, a survey on accessibility and real-life application of NIV was developed by the authors. The questionnaire was circulated for consultation with recognised experts in the field. A consensus was reached after three rounds of redistribution and discussion, and the final document was accepted.

The survey was aimed at members of the European Respiratory Society (ERS). As the ERS is a global scientific organisation that incorporates both physicians and allied health professionals, it was hoped that the assessed sample would provide responses from all groups of medical professionals. The survey was sent to the NIV Support Group in the ERS Respiratory Intensive Care Assembly. To ensure representative sample assessment, the survey was also sent to all ERS National Delegates using the SurveyMonkey ([www.surveymonkey.com](http://www.surveymonkey.com)) online survey platform. The survey was opened in August 2014.

The responses obtained were grouped according to country region and country income based on World Bank definitions (low-income economies (LIEs), lower-middle-income economies (LMIEs), upper-middle-income economies (UMIEs) and high-income economies (HIEs)) ([tables 1](#TB1){ref-type="table"} and [2](#TB2){ref-type="table"}) \[[@C5]\].

###### 

Regional grouping

  **Region description \[5\]**                                                                                                                                          **Countries included**                                                                                                                                       **Region level**
  --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  **Asia, Australia and Oceania**                                                                                                 Armenia, Australia, China, India, Lebanon, New Zealand, Pakistan, Philippines, Saudi Arabia, Turkey                                                                                                       1
  **America**                                                                                                                                                    Argentina, Brazil, Canada, Chile, USA                                                                                                                                      2
  **Africa**                                                                                                                                                         Egypt, South Africa, Tunisia                                                                                                                                           3
  **Europe**                         Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Macedonia, Norway, Poland, Portugal, Republic of Moldova, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, the Netherlands, UK          4

###### 

Income-related grouping

  **Income description (GNI per capita) \[5\]**                                                                                                                            **Countries included**
  --------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Low-income economies (≤USD1005)**                                                                                                                                           No responses
  **Lower-middle-income economies (USD1006--3955)**                                                                                              Armenia, Egypt, India, Pakistan, Philippines, Republic of Moldova, Tunisia
  **Upper-middle-income economies (USD3956--12** **235)**                                                          Argentina, Bosnia and Herzegovina, Brazil, Bulgaria, China, Croatia, Lebanon, Macedonia, Romania, Russia, Serbia, South Africa, Turkey
  **High-income economies (≥USD12** **236)**                 Australia, Austria, Belgium, Canada, Chile, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, New Zealand, Norway, Poland, Portugal, Saudi Arabia, Slovakia, Slovenia, Spain, Switzerland, the Netherlands, UK, USA

GNI: gross national income.

Statistical analysis {#s2b}
--------------------

Survey results were summarised with the use of nonparametric statistics. To determine whether there were region- or income-related differences, we performed a univariate analysis using the Chi-squared test. Logistic regression analysis was performed to control for potential confounding effects of income and region. Statistical inference was based on p\<0.05.

Results {#s3}
=======

Response {#s3a}
--------

Replies to the survey were collected from 161 respondents from 46 countries worldwide ([tables 1](#TB1){ref-type="table"} and [2](#TB2){ref-type="table"}), with a response rate of 42.5%. However, there were no responses from LIEs. There were no relevant differences in sex or age distribution in the means of regional or national income.

Staff members and training {#s3b}
--------------------------

Medical doctors (p=0.009) were found to be the most frequently involved in NIV provision in all economies and regions (73.3%), whereas nurses and respiratory therapists involved in NIV provision represented only 14.3% and 11.2%, respectively. Only 20% of respondents were trained during their medical school education and this was not related to region or income.

NIV access and constraints {#s3c}
--------------------------

According to the univariate analysis, there were no region- or income-related differences concerning: medical specialisation most involved in NIV provision, setting where medical doctor training takes place, speciality of medical doctors who take part in postgraduate NIV training, reimbursement based on disease groups in acute respiratory failure, setting where NIV may be performed in acute respiratory failure, as well as in the way in which practical NIV training takes place (all p\>0.05). There were also no differences in the age or sex of respondents (all p\>0.05). All other responses that were found to reveal income- or region-related differences in NIV limitations are presented in [table 3](#TB3){ref-type="table"}. The univariate analysis revealed that global differences in NIV accessibility and limiting factors are dependent on income rather than region ([table 3](#TB3){ref-type="table"}).

###### 

Univariate regional and financial survey analysis

  **Question**                                                                                             **Region-dependent differences**                                      **Income-dependent differences**                                                                                         
  -------------------------------------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------- ----------
  **Who is mostly involved in NIV practical provision?**                                                Medical doctors in regions 1, 3 and 4                                                  0.03                                                    Medical doctors in all economies                      0.04
  **Is there a reimbursement when NIV is used to manage ARF?**                                         Only with private insurance in region 4                                                 0.04                                                               Not present                               \>0.05
  **NIV in ARF is reimbursed only if it is applied in: ...**                                            Intensive care unit in regions 3 and 4                                                 0.04                                                               Not present                               \>0.05
  Respiratory ward in region 1                                                                                           0.02                                                                                                                                                                             
  **What are the reasons for the inappropriate use of NIV in ARF?**                                             Setting in all regions                                                         0.05                                                      Financing in LMIEs and UMIEs                       0.008
  **What are the factors that limit the use of NIV in ARF?**                                                   Financing in all regions                                                        0.05                                                      Financing in LMIEs and UMIEs                       0.001
  **What are the determinants for reimbursement of home NIV in patients with CRF?**                Independent of disease or insurance in region 4                                           \<0.0001                                             Independent of disease or insurance in HIEs              \<0.0001
  Dependent on disease in regions 1 and 3                                                                              \<0.0001                                                    Dependent on disease in UMIEs                                                   \<0.0001                               
                                                                                                                                                                             Not reimbursed; patients may pay in LMIEs                                             \<0.0001                               
  **What are the underlying diseases covered by the reimbursement for home NIV?**                                COPD in all regions                                                           0.04                                            COPD and chest wall deformities in UMIEs and HIEs            0.003
                                                                                                                                                                             Neuromuscular diseases in UMIEs and HIEs                                                0.009                                
                                                                                                                                                                        Obesity hypoventilation syndrome in UMIEs and HIEs                                          0.0002                                
                                                                                                                                                                          End-stage lung disease palliative care in HIEs                                             0.006                                
                                                                                                                                                               Not reimbursed in all economies in diffuse interstitial lung diseases                                \>0.05                                
  **What are the reasons for the inappropriate use of home NIV in a chronic setting?**                       Financing in regions 1 and 3                                                     0.0001                                                       Setting in all economies                          0.04
                                                                                                             Equipment in LMIEs and UMIEs                                                      0.007                                                                                                      
                                                                                                             Financing in LMIEs and UMIEs                                                    \<0.0001                                                                                                     
  **What are the factors that limit home NIV in CRF?**                                                        Financing in regions 1--3                                                      \<0.0001                                                    Financing in LMIEs and UMIEs                      \<0.0001
                                                                                                             Equipment in LMIEs and UMIEs                                                      0.005                                                                                                      
                                                                                                                Staff in all economies                                                         0.009                                                                                                      
                                                                                                              Legal regulations in LMIEs                                                      0.0007                                                                                                      
  **At the moment NIV is reimbursed in both an acute and chronic setting in: ...**          Indications are based on government regulations in all regions                                     0.03                                    All indications based on government regulations in UMIEs and HIEs   \<0.0001
                                                                                          No and probably will be not reimbursed in the near future in LMIEs                                 \<0.0001                                                                                                     

NIV: noninvasive ventilation; ARF: acute respiratory failure; CRF: chronic respiratory failure; COPD: chronic obstructive pulmonary disease; HIE: high-income economy; UMIE: upper-middle-income economy; LMIE: lower-middle-income economy. See tables 1 and 2 for region- and income-related groups.

Multivariate logistic regression analysis was performed to determine globally the independent NIV limitations after exclusion of possible confounding factors. The analysis revealed that financing in LMIEs and UMIEs is responsible for the major limitation in NIV implementation in acute (p=0.007) and chronic respiratory failure (p\<0.0001).

In the assessment of risk factors responsible for limitation of home NIV in chronic respiratory failure, it was confirmed by logistic regression analysis that financing was relevant in regions 1 and 3 (p=0.02). In the income-level-based assessment analysis, financing was recognised as important in LMIEs and UMIEs (p\<0.0001), equipment was recognised as an important factor in LMIEs and UMIEs (p=0.03), medical understaffing was recognised to be relevant in all economies (p=0.02), and legal regulations were recognised to be relevant in LMIEs (p=0.0005).

NIV reimbursement {#s3d}
-----------------

There were no region- or income-related economic differences in the disease groups during the course of which NIV could have been reimbursed to treat acute respiratory failure patients. There were no significant differences in the influence of hospital setting on NIV reimbursement in acute respiratory failure.

The logistic regression analysis assessment confirmed that reimbursement for home NIV was independent of the underlying disease and of supplementary health insurance in HIEs (p\<0.0001), and dependent on the underlying disease in UMIEs (p\<0.0001). Domiciliary NIV was not provided in LMIEs, but patients could pay for the service/machine themselves (p\<0.0001). Home NIV was found to be reimbursed if utilised for chronic respiratory failure during the course of COPD in UMIEs and HIEs (p=0.009), neuromuscular diseases in UMIEs and HIEs (p=0.02), obesity hypoventilation syndrome in UMIEs and HIEs (p=0.0004), chest wall deformities in UMIEs and HIEs (p=0.004), and end-stage lung diseases for palliative care only in HIEs (p=0.02), but home NIV was not reimbursed when utilised in patients with interstitial lung diseases regardless of the national income level.

It was confirmed that NIV in acute and chronic respiratory failure was reimbursed over a whole range of indications based on government regulations in UMIEs and HIEs (p\<0.0001), and was neither reimbursed nor will be reimbursed in the near future in LMIEs (p\<0.0001).

There were no regional or economic burdens restraining NIV implementation in hospital departments, regardless of whether the NIV introduced to hospital treatment was additionally reimbursed.

Discussion {#s4}
==========

The major strength of our study is its global approach. To the best of our knowledge, this was the first survey sent to a significant number of representatives from the various continents representing different levels of economies. The results have shown that financing is recognised worldwide as the most important factor responsible for NIV limitation in both acute and chronic respiratory failure in all economies, but the economic burden is highest in poorer countries ([tables 2](#TB2){ref-type="table"} and [3](#TB3){ref-type="table"}) \[[@C5]\]. Our findings are not in agreement with previously published work indicating that lack of physician knowledge, insufficient respiratory therapist training and inadequate equipment are the most important factors limiting NIV use \[[@C6], [@C7]\]. We have confirmed that medical doctors are still mainly involved in NIV provision, although respiratory therapists are well trained and may be cost-effective in comparison with employing medical doctors at the patient\'s bedside \[[@C8]\]. Unfortunately, respiratory therapists are available only in a minority of countries. For example, in Poland, chronic respiratory failure medical doctors are obliged to routinely visit NIV patients at home, whereas there is a dedicated nurse in high-dependency NIV rooms in hospitals (although the nurse is responsible only for the circuit and mask adjustments, not for settings adjustments or treatment initiation).

Although the aim of our survey was to concentrate on systemic burdens of performed NIV similarly to C[rimi]{.smallcaps} *et al.* \[[@C9]\], we observed that NIV is being performed mostly by pulmonologists and anaesthesiologists, and to a much lesser extent by other specialists. We confirmed that in wealthy countries NIV reimbursement is based mainly on government regulations, which are not necessarily based on current medical guidelines or cost-effectiveness \[[@C1]\]. Unfortunately, chronic NIV use in LMIEs is neither reimbursed nor will be reimbursed in the near future, which indicates an urgent need for medical advocacy. There are also no major regional factors limiting NIV chronic respiratory failure application, with the exception of Africa and Asia.

In addition to the variability usually observed in general practice, there might be even larger differences between declared utilisation and real data concerning the numbers of patients treated. A study by M[aheshwari]{.smallcaps} *et al*. \[[@C7]\] found that, compared with guideline indications, in acute care specialised centres there was a tendency for NIV underuse in real-life situations of acute respiratory failure and acute-on-chronic respiratory failure in the course of AE-COPD and congestive heart failure. This might be even more pronounced in centres without NIV protocols. Another US-based survey found that the most important barriers to practical implementation of NIV in emergency departments were knowledge, availability of randomised controlled data and the time additionally required for NIV implementation \[[@C10]\]. This is partially confirmed by our findings, in which \<20% of respondents indicated having completed their NIV training at the level of a university course. This should be specifically addressed, because NIV training at a university level should be immediately implemented in all regions and economies. In contrast to these findings \[[@C10]\], we found no global (region- or income-related) differences resulting from equipment availability (although we have not assessed department-related local constraints in our survey). This can be explained by the fact that our respondents were mainly pulmonologists and anaesthesiologists who are expected to have more knowledge and practice in NIV application \[[@C11]\]. It should be emphasised that even in Canada and Europe, where NIV treatment is popular, unjustified underuse of NIV has been reported \[[@C12]--[@C14]\]. In contrast to the previous survey prepared by the ERS Respiratory Intensive Care Assembly officers \[[@C15]\], we obtained more responses in our survey from non-European countries and therefore we were able to mirror NIV application not only in Europe, but worldwide. In that previous survey, it was found that NIV was provided by different medical specialists \[[@C15]\], whereas our findings show that NIV is provided most frequently by medical doctors, without any income- or region-related differences in medical speciality. Identifying factors that limit NIV application is of high importance, especially because NIV may prolong life and improve the patient\'s quality of life in many common diseases or clinical situations \[[@C1], [@C9], [@C16]\]. In general, the fast increase in NIV use and improving success rates are nowadays secondary to a better choice of candidates and timing \[[@C17], [@C18]\]. Unfortunately in COPD, even in European countries, NIV is frequently not implemented in clinical practice and there is a general underuse of NIV, including in situations such as AE-COPD \[[@C19]\]. This was mirrored by our findings, according to which AE-COPD was not considered as an independent indication for NIV reimbursement. Our survey was concentrated on global systemic aspects, and therefore we were not able determine whether NIV was used according to guidelines in terms of timing and clinical indications. Thus, in centres which confirmed implementing NIV, we are not able to verify that that the method is being used in an inefficient way, delayed or in missed indications \[[@C20]\].

One of the most important and remarkable results of our survey was that financial constraints present in LMIEs have and will have a severely negative impact on NIV development. In those countries NIV is not reimbursed and probably will not be reimbursed in the near future, and therefore there is a high probability that in many centres NIV will not be used or will be provided in an unattended setting. On top of this, we need to emphasise that we did not obtain any responses from LIE countries, suggesting that NIV might not be used in those countries. This situation predisposes to underuse and/or application of low-standard, unattended NIV, which could be responsible for much worse treatment outcomes than observed in controlled studies. Therefore, it seems to be crucial to advocate for NIV usefulness and a minimal acceptable setting at a government or regional level (*e.g*. "intermediate" dependency units) \[[@C21]\].

It has been proven that implementation of standards can improve treatment of AE-COPD in emergency departments \[[@C22]\]. Most respondents indicated that NIV skills are gained during specialisation training or by themselves from the medical literature, but this was not dependent on region or income level. There was also an increasing number of respondents from all economies who gained their skills in NIV provision at an ERS school course and/or during an ERS postgraduate course. This shows that medical employees in all countries are interested in respiratory training and are keen to travel abroad for the highest international standard NIV training.

Study limitations {#s4a}
-----------------

One of the most important study limitations is that the survey was not translated from English into other native languages. Thus, we need to take into account that there might have been some misunderstanding about the questions as a result of language barriers. However, the questionnaire was sent to ERS members, which is known to be an English-speaking society. The accuracy and representativeness of our survey can be confirmed by similar epidemiological findings defined by age, profession and setting reported in our previous survey \[[@C15]\] or previous results of the Eurovent survey \[[@C2]\]. Thus, we conclude that language barriers should not have biased our survey results.

Another limitation of our study is the fact that we have no responses from LIEs and only a poor response from Africa (represented by just three countries). We need to take into consideration that, according to the best of our knowledge, until now there has been absolutely no data concerning NIV in Africa and in LIEs. This requires further actions, such as establishing contact with national respiratory societies of those countries or, in cases where no such societies exits, with the relevant ministry of health to reveal whether NIV is not used in those countries or whether the low response was caused by the underrepresentation of LIE members in the ERS. However, considering that the ERS is a global scientific organisation, which incorporates both physicians and allied health professionals from most nations, representing all continents and economies, no responses from LIEs was surprising to some extent. Noting that there are obviously huge differences in the practical implementation of NIV, the survey authors expected that there might be fewer responses from LIEs. Unfortunately, although the invitation to take part in the survey was sent out a number of times, we were not able to achieve a higher response rate.

Another limitation is the overrepresentation of pulmonologists (88%) and medical doctors (90.7%). The only way to avoid this would be to create a future survey addressed not only to ERS members, but also to other societies, such as those for anaesthesiologists, intensivists, respiratory nurses and respiratory therapists. The accuracy of our data is supported by the fact that in comparison to other more local surveys, we were able to obtain global data from all continents but unfortunately with the exception of LIEs \[[@C10], [@C12]--[@C14]\]. Moreover, there was a low representation of respiratory nurses and physiotherapist. To some extent, this was foreseen and discussed at the time of survey distribution. It was decided that the survey would be distributed among ERS Respiratory Intensive Care Assembly members and National Delegates for the following reasons. 1) ERS members may be members of more than one assembly and therefore members of the Allied Respiratory Professionals Assembly interested in NIV were probably also members of the Respiratory Intensive Care Assembly. 2) Although most ERS National Delegates are probably not directly involved in NIV provision, they should have a general knowledge about their national situation. Taking into account that in a medical society such as the ERS there is an obvious predominance of medical doctors, we have managed to obtain responses from nurses (0.7%), respiratory therapists (5.3%) and other healthcare professionals (3.3%). Moreover, according to our results medical doctors are mostly involved in NIV practical provision (73.3%). This suggests that respiratory therapists are currently involved only in a minority of countries.

A further study limitation was the fact that we have not asked specific respondents who pointed out the importance of financial issues for solutions and further explanations. This was for two reasons: 1) the study protocol did not aim to change the current situation, which was not known at the study planning stage, and 2) we found that there were larger income- than region-dependent reasons limiting NIV use. Considering the global scale of our survey, it was impossible to address, predict and automatically provide solutions to particular locally important factors limiting NIV use. Obviously, taking into account the different medical systems, the survey results obtained showed huge differentiation among countries. We found that local country-specific constraints may be significantly different from regional issues; therefore, in order to provide solutions, smaller, more detail surveys would have been more useful. Thus, there is an urgent need for an official chronic respiratory failure NIV treatment guideline, similar to the recently published ERS/American Thoracic Society clinical practice guideline for acute respiratory failure \[[@C23]\], but enriched in economic and cost-effectiveness factors.

A final, but unfortunately important study limitation, which was not foreseen at the survey planning stage, was the small number of questions concerning NIV education and training. Although there were no region- or income-related differences, the survey revealed that NIV training took place during a university course for \<20% of respondents. This was not analysed in detail here because we consider that NIV education/training needs another set of questions, which would have resulted in a longer survey and a much lower response rate.

Conclusions {#s4b}
-----------

Financial constraints are still considered as the major factor limiting NIV use in chronic respiratory failure, especially in LMIEs and UMIEs. Although NIV is rarely studied or practically trained at the stage of university education, there are no major (region- or income-related) differences in NIV teaching.
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